![Mereo BioPharma Group PLC](/common/images/company/N_MREO.png)
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad... Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Show more
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (โMereoโ or the โCompanyโ), a clinical-stage biopharmaceutical company focused on rare diseases, today...
14-month data show treatment with setrusumab resulted inย a large, sustained 67% reduction in annualized fracture rateย and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment...
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (โMereoโ or the โCompanyโ), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.225 | -5.35714285714 | 4.2 | 4.2 | 3.76 | 693232 | 3.93973899 | CS |
4 | 0.215 | 5.71808510638 | 3.76 | 4.34 | 3.26 | 955724 | 3.73207775 | CS |
12 | 1.225 | 44.5454545455 | 2.75 | 4.5 | 2.71 | 1072329 | 3.65058462 | CS |
26 | 0.855 | 27.4038461538 | 3.12 | 4.5 | 2.525 | 1294623 | 3.53992042 | CS |
52 | 2.675 | 205.769230769 | 1.3 | 4.5 | 1.07 | 1262245 | 2.72818026 | CS |
156 | 1.145 | 40.4593639576 | 2.83 | 4.5 | 0.301 | 1427120 | 1.74796853 | CS |
260 | 1.565 | 64.9377593361 | 2.41 | 4.7112 | 0.301 | 1191366 | 2.21652162 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.